Vertex buys the top spot on the list of the biggest preclinical M&A deals. Were they robbed or was it a steal?
The odds of success for the average preclinical drug program are grim, as everyone in R&D can tell you. But that hasn’t stopped the deals in this space from gobbling up more and more cash.
Vertex’s $950 million cash deal to buy Semma and its preclinical stem cell program for diabetes — shooting for a potential cure that combines insulin-producing cells inside a “tea bag” tech for preventing them from sparking an immune response — shot straight to the top of the list of the biggest acquisitions of preclinical assets over the past decade.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.